Roche beats Qiagen in first-line lung cancer personalized therapy
This article was originally published in Clinica
Executive Summary
With the FDA's approval of Roche Molecular Diagnostics' cobas EGFR Mutation test on 14 May, the agency also cleared the way for Genentech and Astellas to market Tarceva (erlotinib) as a first-line therapy for patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) activating mutations, as detected by the new diagnostic.